

Facts about ALS:


- ALS = AMYOTROPHIC LATERAL SCLEROSIS, LOU GEHRIG'S DISEASE, MOTOR NEURON DISEASE (MND)
- CURRENTLY, THERE ARE NO EFFECTIVE TREATMENTS FOR ALS
- EVERY 90 MINUTES, SOMEONE IS DIAGNOSED WITH ALS IN THE US
- IT CAN TAKE A YEAR OR LONGER TO DIAGNOSE ALS
- ABOUT 450,000 PEOPLE ARE LIVING WITH ALS WORLDWIDE
- MOST CASES OF ALS ARE SPORADIC, OCCURRING IN FAMILIES WITHOUT A HISTORY OF THE DISEASE
- AVERAGE SURVIVAL IS 2-5 YEARS FROM DIAGNOSIS
- ALS SHOWS NO PREJUDICE AND AFFECTS PEOPLE OF ALL AGES
- ALS IS NOT A SINGLE DISEASE. EACH CASE IS UNIQUE.

Learn more @ www.als.net



"Every person I meet at ALS TDI has a dedication that cannot be adequately described in words. They give hope to our entire community."

– Kimsu Marder, ALS Advocate



"We have met the people who work at ALS TDI and their passion shines through, their personal connections to this disease drive them. We believe they are one of the most progressive and effective institutes around, and they will be part of the cure."

– Jeremy Truman, ALS Advocate



"I am forever grateful because I know every single person at ALS TDI is working tirelessly to help slow, stop, and end ALS not just a generation from now, but in my lifetime."

– Corey Reich, PALS

ALSTDI is a 501(c)(3) nonprofit organization. Its ID # is 04-3462719. Donations are tax-deductible.



ALS Therapy Development Institute
300 Technology Square, STE 400
Cambridge, MA 02139
TEL: 617.441.7200 FAX: 617.441.7299
EMAIL: info@als.net WEB: www.als.net



Effective Treatments
for Patients Today



“In the end, owning the problem is a simple endeavor. We band together and raise money, and then we spend it on a comprehensive plan that begins with discovery and ends in a pill. We are off to a good start, but we need to go faster, and we need to spend more.”




- Sean Scott, PALS, former President of ALS TDI, 1969-2009



Working to End ALS for Patients Today

The ALS Therapy Development Institute (ALS TDI) is the world's leader in ALS research. Our mission has precise focus: to discover and develop effective treatments to end ALS. As a nonprofit biotech, we are unique; combining the ambition and milestone-driven strategy of a pharmaceutical company with the enterprising and dedicated spirit of a 501c3. This means ALS TDI has incredible flexibility to collaborate and investigate outside the traditional paradigms of drug development, with the goal to expedite promising potential treatments from lab bench to people living with this disease. We were founded by a patient and his family, and that sense of urgency and perseverance drives every decision made at ALS TDI today.

- **More potential therapeutics rigorously screened each year for ALS than the rest of the world**
- **Unbiased approach to research, utilizing small molecules, biologics, gene therapies, and stem cells**
- **Most collaborative ALS organization, resulting in over 15 active partnerships**
- **Funded by over 150 diverse communities, centered around PALS and their families**
- **Spent more on drug development in the last 10 years than any other ALS organization**
- **ALS TDI Clinical Development Outlook: Gilenya® (2014), antiCD40L (2015), antiSOD1 (2015)**



“ALS IS NOT AN INCURABLE DISEASE, IT IS AN UNDERFUNDED ONE.”

- ALS TDI Board Member, Stanley Appel MD, appearing before a congressional hearing in 2009.

It's not just about how much you can raise, it's about how much you are willing to spend on drug discovery and development for people living with ALS today. ALS TDI has spent more money on this goal than any other ALS/MND organization in the world.



“AS A PERSON LIVING WITH ALS, NOTHING GIVES ME GREATER HOPE THAN KNOWING THAT THE TEAM AT ALS TDI IS WORKING FOR ME.”

- Augie Nieto, PALS and Chairman of the Board of Directors at ALS TDI

A donation to ALS TDI is a 100% investment in advancing treatments for patients today. We bring in experienced professionals from the biotech and pharmaceutical industries, invest in cutting-edge technology, and engage in collaborations and partnerships to expedite the time it takes to get potential treatments from lab bench to clinical trial.

In short, we will do whatever it takes to advance our mission and achieve our goal to end ALS.

